Psychiatry Research
July 26, 2025
Giacomo D’andrea, Clara Cavallotto, Mauro Pettorruso et al.
16 citations
INTRODUCTION Anhedonia, defined as the diminished ability to experience or anticipate pleasure, is a core symptom of major depressive disorder (MDD) and bipolar depression (BD), and associated with depression severity, suicidality and poor treatment outcomes. Conventional antidepressants demonstrate limited efficacy against anhedonia. Esketamine nasal spray (ESK-NS) - a novel NMDA receptor...
Journal of Personalized Medicine
April 1, 2025
Marco Di, M. Pepe, Giacomo D’andrea et al.
18 citations
Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies. However, observations integrating patients’ perspective on this treatment are limited. This multicentric Italian study explored experiences with ESK-NS in TRD patients,...
August 4, 2024
Pierfelice Cutrufelli, Antonio Di Francesco, Alessandro Rodolico et al.
eview question / Objective This protocol outlines the methodology for an "Overview of Review" (OoR) study which aims to conduct a comprehensive analysis of systematic reviews with meta-analyses of psilocybin randomized clinical trials.The primary objective is to provide an evaluation of the therapeutic effects, safety profiles, and adverse effects of psilocybin as documented in the best...
Frontiers in Psychiatry
February 1, 2024
Alessandro Rodolico, Pierfelice Cutrufelli, Antonio Di Francesco et al.
28 citations
Background Unipolar and bipolar depression present treatment challenges, with patients sometimes showing limited or no response to standard medications. Ketamine and its enantiomer, esketamine, offer promising alternative treatments that can quickly relieve suicidal thoughts. This Overview of Reviews (OoR) analyzed and synthesized systematic reviews (SRs) with meta-analysis on randomized...